Advertisement

The Nutshell

Daily News Roundup

Most Recent

Columbia neuro employees steal 200K

By | December 12, 2008

Two employees in the pediatric neurological research department at Columbia University were arrested Wednesday (December 10) for scamming the institution out of more than $200,000. John Bzdil, the former manager of the pediatric neurosciences department at the university's Neurological Institute, and his wife, Heather Rinehart, will be presented with charges today (Dec 12) of wire fraud and conspiracy to commit mail fraud and wire fraud, a press officer from the US Attorney's office, Southern D

2 Comments

Grants without peer review?

By | December 12, 2008

University College London is offering new unorthodox research grants for its staff without peer review, deadlines, directives, or milestones. The funding, which is open to any UCL employee, is in in the ballpark of £100,000 ($150,000) per year for at least three years for each awardee, according to UCL visiting earth sciences professor linkurl:Don Braben,;http://www.braben.com/VentureResearch/DB.html the scheme's brainchild and the founder of Venture Research International, a company that

16 Comments

Research halted at Seattle hospital

By | December 11, 2008

Officials have halted enrollment in more than 600 human research studies taking place in Seattle this week after a federal audit found shoddy paperwork in some consent forms. The Department of Veterans Affair's linkurl:Office of Research Oversight;http://www1.va.gov/oro/ determined in a November audit that the linkurl:VA Puget Sound Health Care System;http://www1.va.gov/pugetsound/ should be more careful in documenting that human subjects are competent enough to make reasoned informed consent.

0 Comments

Biotech wants tax break

By | December 10, 2008

Biotech industry executives are beseeching Congress today (10 Dec) for a temporary change in the tax code that would give some struggling biotech companies a cash boost. The plan would funnel hundreds of millions of dollars to some biotechs in exchange for tax credits that the companies would not take if they make money next year and beyond. Nearly a third of publically traded American biotech companies have a six month's or less supply of operating cash, The New York Times linkurl:reported.;h

0 Comments

One bug's coat of many colors

By | December 10, 2008

Parasites can confuse their hosts' immune system by switching the proteins they display on their surface. But how? The intestinal parasite Giardi lamblia harnesses RNA interference to target which surface proteins to shut down, a study published tomorrow in Nature reports. "I actually think it's a superb paper," linkurl:Therdore Nash,;http://www3.niaid.nih.gov/labs/aboutlabs/lpd/gastrointestinalParasitesSection/ chief of gastrointestinal parasitology at the National Institute of Allergy and Inf

1 Comment

Merck bets on generic biologics

By | December 9, 2008

Merck is planning to sell generic copies of blockbuster biotech drugs, the drug maker announced today (Dec. 9) at the annual business briefing at its New Jersey headquarters. Through the newly announced Merck BioVentures division, the company is setting its sights on biotech copycats, which still require their own clinical trials and cost millions to develop. As a result, these drugs are generally priced only marginally lower than branded versions and can still be a lucrative venture. The noti

0 Comments

Nature to retract plant study

By | December 9, 2008

A highly cited __Nature__ paper that identified a long-sought receptor critical for mediating plant response to stress is being retracted after researchers were unable to reproduce the results. Corresponding author on the paper, linkurl:Robert Hill;http://home.cc.umanitoba.ca/~rhill/ from the University of Manitoba, first discovered a problem with the results over the summer when one of his students failed to reproduce the findings. "The binding assay procedures, at least in our hands, did no

4 Comments

New directions for drug discovery?

By | December 9, 2008

The dearth of new drugs coming to market is forcing some drug companies -- and their investors -- to rethink R&D. For instance, at the Novartis Institutes for Biomedical Research (NIBR), the focus has shifted from trying to develop the next blockbuster to reexamining well understood disease pathways to identify drug targets. In a presentation to investors last month, Mark Fishman, president of NIBR, reported that the company has boosted its portfolio of new molecular entities by 40%, and its r

3 Comments

New NIEHS leader looks ahead

By | December 9, 2008

Researchers at NIH's long-beleaguered National Institute of Environmental Health Sciences (NIEHS) are hopeful that the institute's new head, toxicologist linkurl:Linda Birnbaum;http://www.f1000biology.com/about/biography/3056654395292771, will be able to right the ship after the rocky tenure of ex-NIEHS director David Schwartz. linkurl:Chris Portier,;http://www.niehs.nih.gov/about/od/orar/index.cfm associate director of NIEHS, said that there are key differences between Schwartz and Birnbaum. "

0 Comments

Malaria vax passes hurdle

By | December 8, 2008

A malaria vaccine for infants and children -- the group most vulnerable to the disease -- may be heading to phase III trials, according to authors of two studies published online today (Dec. 8) in the New England Journal of Medicine. "The research results show we are one important step closer to malaria joining diseases like small pox or polio that have been either controlled or eliminated by vaccine," said Christian Loucq, director of linkurl:PATH Malaria Vaccine Initiative;http://path.org/ du

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Mettler Toledo
BD Biosciences
BD Biosciences